Compound library / Heart & circulation / Blood Thinners

Warfarin (Coumadin)

Vitamin K antagonist anticoagulant, the longest-established oral blood thinner; requires regular INR blood testing to stay in a safe dosing range.

CategoryBlood Thinners
Regulatory standingNo approved product cited
Typical routeOral
Half-life~20-60 hours
Common dose rangeIndividualized (commonly 2-10 mg/day) based on regular INR testing
Typical cycle lengthOngoing, long-term

BioHack Track models Warfarin (Coumadin) at a half-life of 40 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Oral tablet; no reconstitution needed.

Storage

Store at room temperature, away from light.

Cautions

Prescription medication with a narrow safety margin. Major bleeding risk; interacts with many foods (vitamin K-rich greens) and drugs. Requires routine INR monitoring.

Track Warfarin (Coumadin) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Blood Thinners

What the evidence says

Evidence Check asks 10 questions about every compound. For Warfarin (Coumadin) it can answer 2 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.

Strongest EvidenceBone density

Meta-analyses or systematic reviews exist — the highest grade of evidence there is, whatever they conclude. Read them.

  • Risk of osteoporosis in patients treated with direct oral anticoagulants vs. warfarin: an analysis of observational studiesMeta-Analysis · Front Endocrinol (Lausanne) · 2023 · PMID 37842293
Strongest EvidenceWeight loss

Meta-analyses or systematic reviews exist — the highest grade of evidence there is, whatever they conclude. Read them.

  • Obese patients with atrial fibrillation are more efficiently protected from thrombosis under warfarin or xabans compared to non-obese patients; a systematic review and Meta-analysis of six randomized controlled trialsMeta-Analysis · Thromb Res · 2024 · PMID 38696925

Look up the research

These open a search of each database for Warfarin (Coumadin) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Selected published studies

11 papers naming Warfarin (Coumadin) in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support